Charles River Laboratories International (NYSE:CRL) Hits New 1-Year High – What’s Next?

Charles River Laboratories International, Inc. (NYSE:CRL) shares hit a new 52-week high during trading on Monday . The stock traded as high as $288.64 and last traded at $288.4150, with a volume of 350686 shares. The stock had previously closed at $280.05.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. TD Cowen boosted their target price on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Barclays reissued an “overweight” rating and set a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Finally, Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $255.65.

Charles River Laboratories International Price Performance

The firm has a market capitalization of $13.35 billion, a price-to-earnings ratio of -57.65, a PEG ratio of 2.90 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The business has a 50-day moving average price of $228.65 and a two-hundred day moving average price of $192.02.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Insider Buying and Selling

In other news, CAO Michael Gunnar Knell sold 6,645 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the transaction, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 129,817 shares of company stock valued at $31,774,935 in the last three months. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in shares of Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after buying an additional 1,074 shares during the period. Empowered Funds LLC acquired a new stake in Charles River Laboratories International in the 1st quarter valued at approximately $418,000. American Century Companies Inc. raised its stake in Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after acquiring an additional 1,616 shares in the last quarter. Brown Advisory Inc. raised its stake in Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after acquiring an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after acquiring an additional 3,198 shares during the period. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.